1 BTC
=
- USD
Definium Therapeutics, Inc. Common Shares
As of May 30, 2026 at 24:05 UTC
Chart
About Definium Therapeutics, Inc. Common Shares
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
Market Statistics
Trading Metrics
How to Buy DFTX
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy DFTX
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
3 articlesTrump's April 2026 executive order supporting psychedelic drugs has boosted the psychedelics industry. The FDA awarded priority vouchers to select companies, accelerating drug review timelines. Three biotech firms—Compass Pathways, AtaiBeckley, and Definium Therapeutics—have seen significant stock surges. While analysts remain bullish with high upside targets, these remain speculative investments with substantial risks.
President Trump signed an executive order to fast-track FDA approval of psychedelic treatments for mental disorders, reducing review times from 6-10 months to 1-2 months. The order also allocates $50 million for private sector research. Three biotech companies with breakthrough therapy designations saw significant stock gains following the announcement.
Five psychedelic biotech companies are advancing toward Phase 3 trials for treating depression and anxiety disorders. Helus Pharma reported positive Phase 2a results for SPL026 in major depressive disorder published in Nature Medicine. AtaiBeckley, Definium Therapeutics, GH Research, and LB Pharmaceuticals are all progressing late-stage clinical programs with multiple Phase 3 readouts expected in 2026, signaling the sector's maturation toward regulatory approval.
